newsfilter
← Earnings
Earnings Releases·

Pulse Biosciences — Third Quarter 2026 Earnings Summary

  • Revenue increased to $0.4 million from $0.1 million year-over-year, while GAAP net loss widened to $23.1 million from $19.4 million.
  • Raised $95.8 million in net proceeds via ATM programs, bringing total cash and marketable securities to $189.2 million with less than 6% dilution.
  • Completed enrollment in the NANOPULSE-AF U.S. IDE pivotal study three months ahead of schedule; PRECISE-BTN study enrollment finished in September.
  • Guidance indicates Vybrance commercial launch continuing into Q4 2027, CE Mark approval for nPulse Cardiac Catheter System expected in Q4 2027, and IDE submission for persistent AF study in Q4 2026.
  • Cash used in operating activities was $15.3 million for the quarter, with $7.5 million in annual interest income generated.
Company
PULSE BIOSCIENCES INC
Sector
Healthcare
Industry
Medical Instruments & Supplies